Self‐Cascade API Nanozyme for Synergistic Anti‐Inflammatory, Antioxidant, and Ferroptosis Modulation in the Treatment of Corneal Neovascularization
Small · 2025
DOI: 10.1002/smll.202407751 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2025. Verfasst von Hongwei Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory Cultivation Base Shandong Key Laboratory of Eye Diseases, Eye Institute of Shandong First Medical University, Qingdao, 266071, C…. Hauptthemen laut MEDLINE: Antioxidants, Anti-Inflammatory Agents, Corneal Neovascularization, Ferroptosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Major Basic Research Project of the Natural Science Foundation of Shandong Province, Taishan Scholar Program.
Abstract (Originalsprache)
Corneal neovascularization is a common pathological ocular change that can severely impairs vision, potentially leading to blindness. Although steroids and non‐steroidal anti‐inflammatory drugs are the primary treatments, their side effects, such as ocular hypertension, eye irritation, and corneal lysis, limit their widespread use. In the present study, an active pharmaceutical ingredient (API) nanozyme (PC‐DS NE) is developed through the metal–organic coordination of ferrous sulfate with the anti‐inflammatory agent diclofenac sodium and the natural antioxidant proanthocyanidin. PC‐DS NE exhibited a spheroid morphology with a particle size of 39.7 ± 5.2 nm, and could achieve the short‐term release of diclofenac sodium and sustained release of proanthocyanidin. Notably, the PC‐DS NE possessed favorable biocompatibility, self‐cascade redox regulation capacity, and significant anti‐inflammatory activity. In corneal alkali burn experiments, PC‐DS NE effectively inhibited corneal neovascularization by scavenging reactive oxygen species, inhibiting the expression of inflammatory cytokines and pro‐angiogenic factors, and down‐regulating ferroptosis. These synergistic effects highlighted the potential of PC‐DS NE as a promising treatment for ocular inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory Cultivation Base Shandong Key Laboratory of Eye Diseases, Eye Institute of Shandong First Medical University, Qingdao, 266071, China.
- School of Ophthalmology, Shandong First Medical University, Jinan, 250062, China.
- The Affiliated Women's and Children's Hospital of Ningbo University, Ningbo, 315000, China.
- Medical College, Qingdao University, Qingdao, 266073, China.
- Eye Hospital of Shandong First Medical University, Jinan, 250117, China.
ORCID-Profile: Hua Gao
Förderung
- National Natural Science Foundation of China
- Major Basic Research Project of the Natural Science Foundation of Shandong Province
- Taishan Scholar Program
- Joint Innovation Team for Clinical & Basic Research
- Academic Promotion Program of Shandong First Medical University
- Innovation Project of Shandong Academy of Medical Sciences
Zitieren
APA
Wang, H., Yang, Y., Yu, H., Ma, L., Qi, X., Qu, J., Zhang, X., Li, N., Dou, S., Liu, X., Wei, C., & Gao, H. (2025). Self‐Cascade API Nanozyme for Synergistic Anti‐Inflammatory, Antioxidant, and Ferroptosis Modulation in the Treatment of Corneal Neovascularization. Small. https://doi.org/10.1002/smll.202407751
Vancouver
Wang H, Yang Y, Yu H, Ma L, Qi X, Qu J, et al. Self‐Cascade API Nanozyme for Synergistic Anti‐Inflammatory, Antioxidant, and Ferroptosis Modulation in the Treatment of Corneal Neovascularization. Small. 2025. doi:10.1002/smll.202407751
BibTeX
@article{Wang2025,
author = {Wang, Hongwei and Yang, Yang and Yu, Huimin and Ma, Li and Qi, Xia and Qu, Junpeng and Zhang, Xiaoyu and Li, Na and Dou, Shengqian and Liu, Xiaoxue and Wei, Chao and Gao, Hua},
title = {Self‐Cascade API Nanozyme for Synergistic Anti‐Inflammatory, Antioxidant, and Ferroptosis Modulation in the Treatment of Corneal Neovascularization},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202407751}
}
EUVIMED